Application of rutaecarpine in treating psoriasis

Abstract

The invention relates to an application of 8, 13-Dihydro-indolo [2',3':3,4] pyrido [2,1-b] quinazolin-5 (7H)-one compound (rutaecarpine) in treating the psoriasis. When the psoriasis is treated by the substance, the substance is partially applied in the form of ointment, gelling agent, sticking stuff, lotion, liniment and film coating agent and the like. The structure formula of the rutaecarpine is as follows: C16H13N3O.

Description

technical field The invention relates to a new application of evodiamine. Background technique Psoriasis is a chronic skin disease with immune abnormalities under polygenic genetic background. It has attracted much attention in the field of dermatology clinical and scientific research because of its high incidence and recurrence rate, and mainly involving young adults. The characteristic pathological changes of psoriasis are infiltration of inflammatory cells (especially T lymphocytes) around blood vessels in the superficial dermis, and excessive proliferation of keratinocytes. The pathogenesis of psoriasis has not been fully elucidated. Peripheral blood T lymphocytes infiltrate into the dermis through chemotaxis and are activated, and then produce IL-6, IL-8, INF-γ and other cytokines in the process of psoriasis. important role in development. Recent literature reports that the expression of certain sensory neurotransmitters (such as substance P and vasoactive intestinal ...

AI Technical Summary

Problems solved by technology

The above-mentioned patents do not contain or similarly deduce the therapeutic effect of the compound of the present invention on psoriasis, and there is no patent disclosure of its external anti-psoriasis

Images